Progestin contraceptives

Journal of Midwifery and Women's Health

Volumn 47, Issue 3, 2002, Pages 157-166

  Schnare, Sharon Myoji ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; DIMETICONE; DROSPIRENONE; ELCOMETRINE; ESTRANE DERIVATIVE; ESTROGEN; ETHINYLESTRADIOL; ETONOGESTREL; ETYNODIOL DIACETATE; GESTAGEN; GESTODENE; HYDROXYPROGESTERONE; INJECTABLE CONTRACEPTIVE AGENT; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; MICROVEL; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; NORGESTIMATE; NORGESTREL; NORGESTRON; NOROD; ORAL CONTRACEPTIVE AGENT; POSTCOITUS CONTRACEPTIVE AGENT; PROGESTERONE;

ACNE; AMENORRHEA; ARTICLE; BLEEDING; BREAST DISEASE; CONTRACEPTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG IMPLANT; DRUG METABOLISM; DRUG PELLET; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LUNG EMBOLISM; METHODOLOGY; NAUSEA AND VOMITING; PATIENT SELECTION; SIDE EFFECT; VEIN THROMBOSIS; WEIGHT GAIN; REVIEW;

CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, POSTCOITAL; DESOGESTREL; DRUG IMPLANTS; FEMALE; HUMANS; INTRAUTERINE DEVICES; LEVONORGESTREL; MEDROXYPROGESTERONE 17-ACETATE; NORETHINDRONE; PROGESTINS;

EID: 0035984010     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9523(02)00230-1     Document Type: Article

References (42)

1. Drospirenone-A new progestogen with antimineralocorticoid activity, resembling natural progesterone
2. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids
3. Improving access and quality of care in family planning: Medical eligibility criteria for contraceptive use
4. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
5. Third generation oral contraceptives: Caution is still justified
6. Hemostaic effects of third-and second-generation oral contraceptives: Absence of a causal mechanism for a difference in risk of venous thromboembolism
7. Oral contraceptives and cardiovascular risk-an end to the debate?
8. Oral contraceptives and cardiovascular outcomes: Cause or bias?
9. Mechanism of action of hormonal preparations used for emergency contraception: A review of the literature
10. Oral contraception and congenital malformations in offspring: A review and meta-analysis of the prospective studies
11. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception
12. New approaches to emergency contraception
13. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate
14. Use of oral contraceptives by women with epilepsy
15. Contraceptive methods for women with neurologic disorders
16. Neuroactive steroids and seizure susceptibility
17. Medroxyprogesterone acetate and homozygous sickle cell disease
18. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation
19. Progestogen-only contraceptives during lactation. I. Infant growth
20. Progestogen-only contraceptives during lactation. II. Infant development
21. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer
22. Reduced risk of pelvic inflammatory disease with injectable contraceptives
23. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg. 1. Contraceptive efficacy and side effects
24. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives
25. Metabolic parameters, bleeding, and weight changes in U.S. women using progestin only contraceptives
26. Clinical trial with 3-keto desogestrel subdermal implants
27. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel
28. One year contraception with a single subdermal implant containing nomegestrel acetate (Uniplant)
29. Clinical trial with Nestorone subdermal contraceptive implants
30. Levonorgestrel-releasing (20 μg/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives
31. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy
32. Treatment of adenomyosis-associated menorrhagia with levonorgestrel-releasing intrauterine device
33. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding
34. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient
35. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy
36. Protective effect of intrauterine release of levonorgestrel on pelvic infection: Three years comparative experience